ストックスクリーナーアプリを入手
0.00
100.00%
-15.96
前日終値:
$15.96
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$22.12M
収益：
$20.97M
当期純損益:
$-118.51M
株価収益率:
0.00
EPS:
-2.19
ネットキャッシュフロー:
$-94.45M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$19.08
Cara Therapeutics Inc Stock (CARA) Company Profile
名前
Cara Therapeutics Inc
セクター
電話
203-406-3700
住所
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
CARA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CARA
Cara Therapeutics Inc
|
0.00 | 22.12M | 20.97M | -118.51M | -94.45M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
375.63 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.80 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.10 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
672.35 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.29 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-14 | 開始されました | Raymond James | Outperform |
| 2025-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 開始されました | Piper Sandler | Overweight |
| 2025-05-21 | 開始されました | Oppenheimer | Outperform |
| 2025-05-15 | 開始されました | BTIG Research | Buy |
| 2024-06-13 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | ダウングレード | Needham | Buy → Hold |
| 2024-06-13 | ダウングレード | Stifel | Buy → Hold |
| 2023-03-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-03-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 再開されました | Canaccord Genuity | Buy |
| 2021-08-03 | 開始されました | JP Morgan | Neutral |
| 2020-04-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-29 | 繰り返されました | Laidlaw | Buy |
| 2019-02-06 | 再開されました | Jefferies | Buy |
| 2019-01-15 | 開始されました | BofA/Merrill | Neutral |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 開始されました | Jefferies | Buy |
| 2018-08-08 | 繰り返されました | Stifel | Buy |
| 2018-06-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-12 | 再開されました | H.C. Wainwright | Buy |
| 2018-02-12 | アップグレード | Janney | Neutral → Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2017-06-30 | ダウングレード | Janney | Buy → Neutral |
| 2017-06-30 | 繰り返されました | Laidlaw | Buy |
| 2017-06-30 | 繰り返されました | Stifel | Buy |
| 2017-03-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-03-28 | 繰り返されました | Laidlaw | Buy |
| 2017-03-10 | 繰り返されました | Laidlaw | Buy |
| 2016-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2016-08-08 | 繰り返されました | Needham | Buy |
すべてを表示
Cara Therapeutics Inc (CARA) 最新ニュース
Cara Therapeutics Inc to Host Earnings Call - ACCESS Newswire
This ‘Strong Buy’ Stock Could Be the Next Big Biotech Breakout - Yahoo Finance
This ‘Strong Buy’ Stock Could Be The Next Big Biotech Breakout - Barchart.com
Tvardi Therapeutics (NASDAQ:TVRD) Coverage Initiated at Raymond James Financial - Defense World
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - Business Wire
Tvardi Therapeutics director Shaheen Wirk resigns from board - Investing.com Australia
Tvardi Therapeutics director Shaheen Wirk resigns from board By Investing.com - Investing.com Nigeria
Raymond James Initiates Tvardi Therapeutics at Outperform - MarketScreener
Raymond James initiates coverage on Tvardi Therapeutics stock with Outperform rating - Investing.com Nigeria
Equities Analysts Offer Predictions for TVRD FY2025 Earnings - Defense World
Cantor Fitzgerald Initiates Coverage on Tvardi Therapeutics (NASDAQ:TVRD) - Defense World
Tvardi Therapeutics: A Catalyst-Driven Biotech Play with 130% Upside Potential - AInvest
Cantor Fitzgerald initiates coverage on Tvardi Therapeutics stock with Overweight rating - Investing.com
Cantor Fitzgerald Initiates Tvardi Therapeutics at Overweight With $52 Price Target - MarketScreener
Tvardi Therapeutics, Inc.(NasdaqCM: TVRD) added to Russell Microcap Growth Index - MarketScreener
Cara Therapeutics (NASDAQ:TVRD) Now Covered by Analysts at Piper Sandler - Defense World
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga
Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - MarketScreener
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com Canada
How To Trade (CARA) - news.stocktradersdaily.com
Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages - Defense World
Oppenheimer Begins Coverage on Cara Therapeutics (NASDAQ:TVRD) - MarketBeat
BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa
BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks
Cara Therapeutics (NASDAQ:TVRD) Raised to “Hold” at Wall Street Zen - Defense World
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World
BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com UK
Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN
Tvardi Therapeutics Reports Q1 2025 Financial Results - TipRanks
Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire
Where are the Opportunities in (CARA) - news.stocktradersdaily.com
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire
Cara Therapeutics Inc (CARA) 財務データ
収益
当期純利益
現金流量
EPS
0.71%
0.30%
大文字化:
|
ボリューム (24 時間):